Ozempic for blood sugar: what the evidence says about GLP-1 use

What did @keroseneskies actually say?

The creator describes using an "osmotic pen" for diabetes and "other conditions," saying they have "diabetes, pre-diabetes, and a host of other health issues" linked to hypothyroidism. They then walk through the injection technique: pressing until the pen goes to zero, holding for six seconds, capping the pen, removing the needle, and disposing of it in a sharps container.

Notably, the creator does not make dramatic weight loss claims or describe getting Ozempic off-label. They frame this as legitimate diabetes management under medical supervision, which is exactly what semaglutide is approved for. The video is mostly a how-to, not a health manifesto.

One thing worth flagging: the creator calls it an "osmotic pen," which is almost certainly a verbal stumble for "Ozempic pen." Osmosis is a different biological mechanism entirely, unrelated to GLP-1 receptor agonists. Small error, but worth noting since this video has 86,000 views.

Does the science back this up?

Yes, with some important nuance. Ozempic (semaglutide) is FDA-approved for type 2 diabetes management, and the connection between hypothyroidism and impaired glucose metabolism is well-documented in endocrinology literature.

Thyroid hormones directly regulate insulin sensitivity and glucose uptake in peripheral tissues. Hypothyroidism is associated with insulin resistance, dyslipidemia, and a higher prevalence of metabolic syndrome. A 2019 meta-analysis by Kapadia et al. in the Journal of Clinical Endocrinology and Metabolism found that subclinical hypothyroidism significantly increases the risk of type 2 diabetes. So the creator's claim that hypothyroidism and blood sugar problems "go hand in hand" is not just anecdote, it reflects real pathophysiology.

The injection technique described, holding for six seconds after the dose indicator hits zero, aligns with Novo Nordisk's prescribing guidelines and standard nursing practice for subcutaneous GLP-1 administration. The sharps disposal instruction is also correct and legally required in most U.S. states.

What did they get wrong (or right)?

Let's be direct: they got more right than wrong here, which is not what you usually say about a 86K-view TikTok about injectable medications.

The injection technique is accurate. Holding the pen for six seconds after the dose reaches zero reduces the risk of medication leakage at the injection site, a common beginner mistake with autoinjector pens. The sharps container instruction is not just good practice, it is federally encouraged under the EPA's guidelines for household sharps disposal.

What's imprecise: the creator says they have both "diabetes" and "pre-diabetes" simultaneously. Clinically, these are mutually exclusive diagnoses. Pre-diabetes is defined by HbA1c between 5.7 and 6.4 percent; a diabetes diagnosis requires 6.5 percent or higher. It's possible they mean they were previously pre-diabetic before progressing to a diabetes diagnosis, or they're describing overlapping labs from different time points. Either way, the phrasing is medically incoherent and could confuse viewers about their own glucose status.

The "osmotic pen" misnomer is minor but worth correcting. Semaglutide works by binding GLP-1 receptors, not through osmotic mechanisms.

What should you actually know?

If you have hypothyroidism and your doctor is flagging blood sugar issues, you are not imagining a connection. The thyroid-glucose metabolism relationship is bidirectional and underappreciated in primary care. Research by Lambadiari et al. (2011, Metabolism) showed that even treated hypothyroid patients can have residual impairments in glucose disposal.

Ozempic is approved for type 2 diabetes, not pre-diabetes or hypothyroidism directly. If you're seeing it prescribed for early-stage glucose dysregulation, that may be reasonable off-label clinical judgment, but it should come from a physician who has reviewed your full metabolic panel, not a TikTok video. Semaglutide carries a boxed warning for a risk of thyroid C-cell tumors observed in rodents. People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use it. Given that this creator already has a thyroid condition, it is worth confirming their prescriber reviewed that contraindication specifically.

Proper sharps disposal matters. Needle-stick injuries from improperly discarded syringes are a real public health issue. The creator got this right, and it deserves a mention.

• Semaglutide is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy) only.
• Hypothyroidism and type 2 diabetes frequently co-occur due to shared metabolic pathways.
• Anyone on a GLP-1 agonist with pre-existing thyroid disease should discuss the C-cell tumor risk with their prescriber.
• Sharps must be disposed of in an approved container, not household trash or recycling.